Subscribe

Fourfold Variability Found in Hospital Charges for Stroke Diagnostic Tests

VBCN - July 2014 Volume 1, No 2 - Stroke
Wayne Kuznar

Philadelphia, PA—Some of the most expensive diagnostic tests for stroke or transient ischemic attack (TIA) do not affect patient management but expose patients to potential harm, said Pratik D. Bhattacharya, MD, MPH, Assistant Professor of Neurology, Wayne State University, Detroit, MI.

“At some hospitals, the charge for a single diagnostic test is higher than the Medicare reimbursement for the entire hospitalization,” Dr Bhattacharya said during a poster presentation at the 2014 American Academy of Neur­ology meeting.

Diagnostic testing is a major contributor to hospital charges for stroke and TIA. Neuroimaging was the largest growing cost component of inpatient stroke care from 1999 to 2007, increasing in cost by 213% after adjusting for inflation. A 2009 study from the National Cancer Institute estimated that computed tomography (CT) scans performed in 2007 will cause an excess of 29,000 cancers and 14,500 deaths as a result of radiation exposure.

As part of their study, Dr Bhattacharya and colleagues investigated the variability in cost between tests within a single metropolitan area and the charges for tests of questionable utility.

Hospital charges were ascertained from the website www.newchoice health.com. The least expensive and most expensive charges for a “basic workup,” including brain CT, carotid ultrasound, and transthoracic echocardiography, were computed. Charges for additional tests, such as CT angio­graphy (CTA) and magnetic resonance angiography (MRA) of the brain and neck, were also assessed.
The charges were assessed at hospitals in 1 metropolitan area.

“Necessity was based on clinical trial data,” said Dr Bhattacharya. “For instance, we have a couple of clinical trials published in the past few years that demonstrate that you can detect areas of narrowing in the carotid arteries, but it may not necessarily change your treatment strategy. Based on these data, we suspected that the MRA or CTA may not necessarily change the treatment strategy.”

The charges for individual diagnostic tests ranged from $250 to $8900. The variability in charges for individual tests for the most expensive hospital compared with the least expensive hospital ranged from 2.9 (magnetic resonance imaging [MRI] of the brain) to 8.1 (transesophageal echocardiography). The least expensive charge for a basic workup was $2225 and the most expensive was $8850.

The charges tended to be highest for tests of dubious value, Dr Bhattacharya said. “Based on our practice, we see that they’re ordered very frequently,” he said, “but I don’t know that there’s formal evidence to show how often they are being ordered.”

The tests with charges of at least $5000 at the most expensive hospitals included sleep study ($5100), brain MRI ($6800), neck MRA ($7700), CT angiography of the brain ($8300), neck CT angiography ($8400), brain MRA ($8600), and transesophageal echocardiography ($8900).

Whether transparency in pricing affects costs for common diagnostic tests in stroke requires further study, said Dr Bhattacharya.

Related Items
One-Fourth of Eligible Patients with Stroke Still Not Receiving Thrombolytic Therapy
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Stroke
Hypermobility Syndrome Underrecognized, Requires Team-Based Management
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatic Diseases
Neuropathies in Rheumatic Diseases Encompass Wide Spectrum of Diagnoses
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatic Diseases
Patients with Rheumatoid Arthritis Cite Improvements in Pain, Quality of Life as Treatment Goals
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatoid Arthritis
Celecoxib Demonstrates Better Results than Acetaminophen in Patients with Low Back Pain
Wayne Kuznar
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Back Pain
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Emerging Therapies
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Emerging Therapies
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Lung Cancer
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Breast Cancer
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Melanoma
Last modified: May 21, 2015
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology